Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | SVP, Controllership | March 10, 2025 | March 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 10, 2025 · Filed March 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,077 |
Reported balance
After 2025-03-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-10 · Exercise / conversion · Acquired 1,952 · Balance 40,077 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| Common StockSEC Table I · non-derivative | Direct | 39,453 |
Reported balance
After 2025-03-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-10 · Tax withholding · Disposed 624 · Balance 39,453 F2: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 9,875 |
Reported balance
After 2025-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-10 · Exercise / conversion · Disposed 1,952 · Balance 9,875 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F3: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 12, 2025 22:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009265 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,875 Underlying: Common Stock · 1,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 624 | $117.21 | $73,139.04 |
DisclosureSEC source: 0001127602-25-009265 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009265 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003401 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,787 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting person on March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of the performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting person until the requisite continuing service requirements are met. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · derivative · entry 8 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,827 Underlying: Common Stock · 157 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 157 | $91.86 | $14,421.24 |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · nonDerivative · entry 5 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,078 F2 · kind: Mandatory tax withholding on vesting of restricted stock units due to retirement eligibility. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · nonDerivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029178 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,282 Underlying: Common Stock · 901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 408 | $92.34 | $37,674.72 |
DisclosureSEC source: 0001127602-24-029178 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,078 Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029178 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,183 Underlying: Common Stock · 901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 292 | $81.44 | $23,780.48 |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,585 Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023823 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,084 Underlying: Common Stock · 3,678 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 980 | $73.66 | $72,186.80 |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,976 Read SEC document |
| August 10, 2024 Filed Aug 12, 2024 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,678 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-022009 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,762 Underlying: Common Stock · 901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 255 | $65.25 | $16,638.75 |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,278 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018419 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 4,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · derivative · entry 7 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,663 Underlying: Common Stock · 4,825 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 13,660 | $0.00 Strike: $75.12 | $0.00 |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · derivative · entry 6 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,660 Underlying: Common Stock · 13,660 shares Expires 2034-03-10 F5 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · derivative · entry 5 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,838 Underlying: Common Stock · 1,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 748 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · derivative · entry 4 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,772 Underlying: Common Stock · 748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 790 | $75.12 | $59,344.80 |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · nonDerivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,632 Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 19:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 748 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009708 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 13, 2023 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · derivative · entry 7 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,984 Underlying: Common Stock · 117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 13, 2023 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · derivative · entry 6 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,101 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| December 13, 2023 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 298 | $83.09 | $24,760.82 |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · nonDerivative · entry 4 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,235 F2 · kind: Mandatory tax withholding on vesting of restricted stock units due to retirement eligibility. Read SEC document |
| December 13, 2023 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 13, 2023 Filed Dec 16, 2024 21:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-029490 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029245 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,520 Underlying: Common Stock · 518 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 222 | $79.02 | $17,542.44 |
DisclosureSEC source: 0001127602-23-029245 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,420 Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029245 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,038 Underlying: Common Stock · 519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 149 | $76.00 | $11,324.00 |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,124 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023981 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 4,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,557 Underlying: Common Stock · 4,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,306 | $80.00 | $104,480.00 |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,754 Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022375 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018592 · form4.xml · derivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,041 Underlying: Common Stock · 517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 153 | $78.12 | $11,952.36 |
DisclosureSEC source: 0001127602-23-018592 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,576 Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018592 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,405 | $0.00 Strike: $79.50 | $0.00 |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · derivative · entry 7 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,405 Underlying: Common Stock · 10,405 shares Expires 2033-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 6,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · derivative · entry 6 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,558 Underlying: Common Stock · 6,130 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · derivative · entry 5 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,428 Underlying: Common Stock · 1,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · derivative · entry 4 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 Underlying: Common Stock · 1,601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 801 | $79.50 | $63,679.50 |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 3 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,212 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 2 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009984 · form4.xml · nonDerivative · entry 1 Patterson Sandra · CIK 0001968906 · SVP, Controllership 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.